LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Kura Oncology Inc

Open

SectorHealthcare

6.29 2.44

Overview

Share price change

24h

Current

Min

6.07

Max

6.32

Key metrics

By Trading Economics

Income

-38M

-57M

Sales

-40M

14M

EPS

-0.66

Profit margin

-407.067

Employees

192

EBITDA

-48M

-65M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+275.32% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

14M

540M

Previous open

3.85

Previous close

6.29

News Sentiment

By Acuity

30%

70%

98 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 maj 2025, 23:25 UTC

Hot Stocks

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 maj 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 maj 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 maj 2025, 21:01 UTC

Major Market Movers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 maj 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 maj 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 maj 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 maj 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 maj 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 maj 2025, 23:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 maj 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 maj 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 maj 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 maj 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 maj 2025, 23:28 UTC

Earnings

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 maj 2025, 23:27 UTC

Earnings

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 maj 2025, 23:26 UTC

Earnings

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 maj 2025, 23:26 UTC

Earnings

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 maj 2025, 23:26 UTC

Earnings

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 maj 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 maj 2025, 23:22 UTC

Top News

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 maj 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 maj 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 maj 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 maj 2025, 23:04 UTC

Top News

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 maj 2025, 21:46 UTC

Top News

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 maj 2025, 21:42 UTC

Top News
Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 maj 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 maj 2025, 21:07 UTC

Top News

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 maj 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

275.32% upside

12 Months Forecast

Average 23.27 USD  275.32%

High 40 USD

Low 10 USD

Based on 13 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

98 / 382 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.